Zobrazeno 1 - 10
of 18
pro vyhledávání: '"M D, Vincent"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
T W, Zhang, G B, Rodrigues, A V, Louie, D, Palma, A R, Dar, B, Dingle, W, Kocha, M, Sanatani, B, Yaremko, E, Yu, J, Younus, M D, Vincent
Publikováno v:
Current oncology (Toronto, Ont.). 25(1)
We designed a phase i study of concurrent chemoradiotherapy (ccrt) with docetaxel (D) and cisplatin (C), followed by consolidation dc, for unresectable stage iii non-small cell lung cancer (nsclc).Patients with histologically proven and unresectable
Publikováno v:
Annals of Oncology
Background This study describes a repeated measures prediction index to identify patients at high risk of ≥ grade 2 hand-foot skin reaction (HFSR) before each week of sorafenib therapy. Methods Data from 451 patients who received a sorafenib (400 m
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 27(12)
Platinum drugs comprise one of the main classes of chemotherapy drugs that can induce remissions in various solid tumors. Although tumors often regress on treatment with cis-diamminedichloroplatinum II (cisplatin) or cis-diammine-1,1-cyclobutane dica
Publikováno v:
British journal of pharmacology. 127(8)
1. Thymidylate synthase (TS), the key enzyme in de novo synthesis of thymidine, is an important target for antitumour chemotherapy. It was hypothesized that antisense oligonucleotide down-regulation of TS mRNA would decrease TS levels and enhance the
Publikováno v:
Journal of Clinical Oncology. 23:756-756
756 Background: Tesmilifene (DPPE), a novel chemopotentiating small molecule, conferred a substantial (50%+) increase in median survival in MA.19, a 305 patient randomized trial in ABC (doxorubicin...
Publikováno v:
European Journal of Cancer and Clinical Oncology. 23:1589-1599
Conventional staging in small cell lung cancer (SCLC) is only of limited prognostic value and is often based on elaborate investigations. We have carried out univariate and multivariate analysis of possible prognostic factors at presentation in 333 c
Publikováno v:
Journal of Clinical Oncology. 5:185-189
Fifty-two previously untreated patients with small-cell lung carcinoma (SCLC) were treated with a combination of carboplatin 300 mg/m2 intravenously (IV) on day 1 and etoposide 100 mg/m2 IV on days 1 through 3 every 28 days for four courses. Patients
Autor:
R. Skeet, Stanley W. Ashley, R. C. Coombes, S. Clarke, T. J. Powles, H. Adcock, M. D. Vincent, J. Gibb, H.L. Thomas
Publikováno v:
European Journal of Cancer and Clinical Oncology. 22:1059-1065
Factors influencing the extremes of survival in disseminated breast cancer were analysed. From a pool of 1066 patients with distant metastatic breast cancer, the 41 patients who had survived 5 yr or more from first distant recurrence were matched wit
Publikováno v:
Cancer chemotherapy and pharmacology. 21(1)
Response to second-line therapy in relapsing patients with small cell lung carcinoma (SCLC) is often claimed to be evidence in favour of non-cross resistance. Fifteen patients with SCLC who had relapsed off treatment after responding to initial first